全身与局部糖皮质激素使用与代谢综合征及体重指数的关联
在荷兰北部一般人群的横断面队列研究(140,879名成人)中,女性整体、全身及局部糖皮质激素使用与代谢综合征患病几率升高相关,局部用药中仅鼻用和吸入型与代谢综合征相关;男性中未发现此关联。局部糖皮质激素(尤其吸入型)与较高体重指数相关。
要点
- 女性整体、全身及局部糖皮质激素使用与代谢综合征患病几率升高相关。
- 女性局部用药中仅鼻用(OR 1.20)和吸入型(OR 1.35)与代谢综合征相关。
- 男性中整体及特定类型糖皮质激素使用与代谢综合征无关联。
核心结论
- 局部糖皮质激素(尤其吸入型)及全身糖皮质激素使用与代谢综合征患病可能性升高、体重指数升高及其他不良心血管代谢特征相关,尤其在女性中。
研究设计与样本
- 横断面队列研究,纳入荷兰北部一般人群的140,879名成人参与者(基于人群的Lifelines队列研究)。
主要发现
- 女性中,整体、全身及局部糖皮质激素使用与代谢综合征患病几率升高相关。
- 女性局部用药者中,仅鼻用糖皮质激素(OR 1.20,95%CI 1.06至1.36)和吸入型糖皮质激素(OR 1.35,95%CI 1.24至1.49)与代谢综合征患病可能性升高相关。
- 男性中,整体及特定类型糖皮质激素使用与代谢综合征患病均无关联。
- 女性中仅使用局部糖皮质激素者、以及两性中吸入型糖皮质激素使用者,与较高体重指数相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Use of systemic corticosteroids (CSs) may induce adverse cardiometabolic alterations, potentially leading to obesity and metabolic syndrome (MetS). Although evidence is accumulating that local CSs have considerable systemic effects, their effects on cardiometabolic factors in the general population remain unclear. OBJECTIVE: To investigate the association between overall CS use and specific CS types with MetS, body mass index (BMI), and other cardiometabolic traits. DESIGN: Cross-sectional cohort study. SETTING: General population from the northern Netherlands. PARTICIPANTS: A total of 140,879 adult participants in the population-based Lifelines Cohort Study. MAIN OUTCOME MEASURES: BMI, waist circumference, systolic and diastolic blood pressure, fasting metabolic serum parameters, and a comprehensive set of potential confounding factors. RESULTS: In women, overall, systemic, and local CS use was associated with higher odds of having MetS. Among local female users, only nasal (odds ratio [OR], 1.20 [95% confidence interval (CI), 1.06 to 1.36]) and inhaled CSs [OR, 1.35 (95% CI, 1.24 to 1.49)] users were more likely to have MetS. In men, no association was found between overall and specific CS use and presence of MetS. Use of local-only CSs in women, specifically inhaled CSs in both sexes, was associated with higher BMI. CONCLUSIONS: Use of local CSs, particularly inhaled types, as well as systemic CSs, was associated with higher likelihood of having MetS, higher BMI, and other adverse cardiometabolic traits, especially among women. Because the inhaled agents are the main group of prescribed CSs, this might be a substantial risk to public health in case of a yet-to-be-proven causal relationship.
引用
- Savas M, Muka T, Wester VL, et al. Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index. J Clin Endocrinol Metab. 2017. PMID: 28973553. doi:10.1210/jc.2017-01133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。